جميع الدراسات
نشط غير مجندالمرحلة 2تدخلي

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

This study is looking into a new medicine called Vamifeport for adults who have a common genetic condition called hereditary hemochromatosis (HFE-HH). This condition causes too much iron to build up in the body, particularly in the liver. The main goal of the study is to find out if Vamifeport can help lower the iron levels in the liver, which will be measured using a special type of MRI scan. To get a clear picture, some participants will receive the new medicine, while others will receive a dummy pill (placebo). This helps researchers understand the true effect of Vamifeport compared to not having the active medicine. The study is in an early stage, called Phase 2, and will involve several medical checks.

نظرة سريعة

الحالة
نشط غير مجند
المرحلة
المرحلة 2
الراعي
CSL Behring
الهدف من التسجيل
84
ابدأ
22 Jan 2026
التاريخ المتوقع للانتهاء
15 May 2028

ما هو موضوع هذه الدراسة؟

This study is exploring a new medicine called Vamifeport for adults who have a condition known as hereditary hemochromatosis (HFE-HH). This is a genetic condition meaning it's passed down in families, and it causes the body to absorb too much iron from food. Over time, this extra iron can build up in organs like the liver, which can cause health problems if not managed.

The main purpose of this study is to see if Vamifeport can safely and effectively reduce the amount of iron stored in the liver. Researchers will use a special type of MRI scan to measure iron levels in the liver before and after treatment. They want to understand how well this new medicine works compared to a 'dummy' pill that contains no active medicine, which is called a placebo. By comparing these two groups, scientists can be more sure about the effects of Vamifeport itself.

This is a Phase 2 study, which means it's an early but important step in developing new medicines. It helps researchers gather more information about how the medicine works, what a good dose might be, and checks for any side effects. The results will help decide if this medicine should be tested in larger studies in the future.

النقاط الرئيسية

  • This study tests a new medicine (Vamifeport) for iron overload in hereditary hemochromatosis.
  • It aims to reduce liver iron levels, measured by special MRI scans.
  • You might receive the new medicine or a dummy pill (placebo).
  • Regular health checks, blood tests, and scans are part of participating.
  • It's a Phase 2 study, an early step in medicine development.
  • يمكنك التوقف عن المشاركة في أي وقت.

من قد يكون مؤهلاً؟

To join this study, you need to be an adult, aged 18 or over, and have signed a form saying you understand the study and agree to take part. A doctor must have already diagnosed you with hereditary hemochromatosis (HFE-HH) in the past. We'll also need to see that you have too much iron in your body currently. This will be checked by blood tests showing specific iron levels and a special MRI scan of your liver showing iron buildup. Your body weight and height (BMI) also need to be within a certain healthy range.

There are also some reasons why you might not be able to join. For example, if you have other serious health problems, unusual blood test results, or heart issues that doctors think are important, you might not be eligible. This is to make sure the study is as safe as possible for everyone involved.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل أنت بالغ (18 سنة أو أكثر)؟
  2. Have you been diagnosed with hereditary hemochromatosis (HFE-HH)?
  3. Do your doctors think you have too much iron in your body currently?
  4. Do you have a healthy body weight for your height?
  5. Do you have any serious ongoing health problems that might make you ineligible?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part, you'll be randomly assigned to one of two groups: one receiving the new medicine, Vamifeport, and the other receiving a dummy pill (placebo). Neither you nor your study doctor will know which you are receiving, which helps make the study fair. You'll take the study medicine or placebo regularly as instructed.

Throughout the study, you'll have several visits to the clinic. These visits will involve various health checks, blood tests, and liver MRI scans to measure your iron levels. There will also be appointments to check on your overall health and look for any changes or side effects. The total duration of your participation in the study will involve initial checks, the period of taking the study medicine, and a follow-up period after you stop taking it.

المخاطر والفوائد المحتملة

Taking part in this study could potentially help reduce the iron overload in your body, which might improve your health if the new medicine, Vamifeport, proves effective. However, as with any new medicine, there's always a possibility of side effects or unknown risks. The study team will carefully monitor your health throughout. You are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (100)

  • Banner MD Anderson
    الرمز البريدي المؤكد
    جيلبرت، الولايات المتحدة
  • Infinity Clinical Trials
    الرمز البريدي المؤكد
    سان دييغو، الولايات المتحدة
  • Medical Oncology Associates of San Diego
    الرمز البريدي المؤكد
    سان دييغو، الولايات المتحدة
  • Green Leaf Clinical Trials
    الرمز البريدي المؤكد
    جاكسونفيل، الولايات المتحدة
  • Global Medical Research Management LLC
    الرمز البريدي المؤكد
    ميامي، الولايات المتحدة
  • مستشفى جامعة إنديانا الصحية
    الرمز البريدي المؤكد
    إنديانابوليس، الولايات المتحدة
  • Ochsner Medical Complex - High Grove
    الرمز البريدي المؤكد
    باتون روج، الولايات المتحدة
  • كلية الطب بجامعة جونز هوبكنز
    الرمز البريدي المؤكد
    بالتيمور، الولايات المتحدة
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders
    الرمز البريدي المؤكد
    بيثيسدا، الولايات المتحدة
  • James M. Stockman Cancer Institute
    الرمز البريدي المؤكد
    Frederick, United States
  • University of Michigan Health System (UMHS)
    الرمز البريدي المؤكد
    آن آربر، الولايات المتحدة
  • Aspirus St. Luke's Clinic - Duluth - Oncology & Hematology
    الرمز البريدي المؤكد
    Duluth, United States

أسئلة شائعة

What is hereditary hemochromatosis (HFE-HH)?

It's a genetic condition where your body absorbs and stores too much iron, which can build up in organs like the liver and cause health problems.

What is a 'dummy pill' or placebo?

A dummy pill looks exactly like the study medicine but doesn't contain any active ingredients. It helps researchers understand the true effect of the medicine being tested.

What does a liver MRI scan involve?

It's a special type of scan that uses strong magnets and radio waves to create detailed pictures of your liver, allowing doctors to precisely measure iron levels there.

Why is this called a 'Phase 2' study?

Phase 2 studies are early stages of drug development. They aim to see if a new medicine works, find a good dose, and check for safety in a larger group of people than initial tests.

هل سأعرف إذا كنت أحصل على الدواء الحقيقي أم الدواء الوهمي؟

No, during the study, neither you nor your study doctor will know whether you are receiving Vamifeport or the placebo. This is to ensure the study results are unbiased.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.